No quarterly revenue total was found in Imunon, Inc.'s SEC filings.
Imunon, Inc. (IMNN) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$3.2 million. As of Jun 30, 2026 it held $6.9 million in cash and investments and $811,190 in total debt.
Revenue
—
Net income
$-2.81M
-2.7% vs year-ago quarter
Operating cash flow
$-3.03M
-2.5% vs year-ago quarter
Free cash flow
$-3.22M
+0.4% vs year-ago quarter
EPS
$-0.54
+74.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
5.61M
+156.0% vs year-ago quarter
Net cash
$6.05M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IMNN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Lawrenceville, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 749647
- Former names
- CELSION CORP (until Sep 19, 2022); Celsion CORP (until Sep 19, 2022); CHEUNG LABORATORIES INC (until Feb 17, 1998)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$2.8M | -$4.3M | -$4.3M | -$3.5M | -$2.8M |
| Net income | -$2.8M | -$4.2M | -$4.2M | -$3.4M | -$2.7M |
| Diluted EPS | -$0.54 | -$0.84 | -$1.45 | -$1.16 | -$2.15 |
| Operating cash flow | -$3.0M | -$4.0M | -$3.7M | -$4.4M | -$3.0M |
| Free cash flow | -$3.2M | — | -$3.7M | -$4.4M | -$3.2M |
| Total assets | $15.0M | $8.0M | $12.3M | $9.0M | $8.8M |
| Total liabilities | $10.8M | $4.7M | $5.2M | $4.9M | $6.1M |
| Stockholders' equity | $4.2M | $3.4M | $7.1M | $4.1M | $2.7M |
| Cash and investments | $6.9M | $4.8M | $8.8M | $5.3M | $4.7M |
| Total debt | $811,190 | $911,752 | $1.0M | $1.1M | $1.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 27, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 21, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Bylaw or fiscal year change
|
Sep 29, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
All 1001 Imunon, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.